Page last updated: 2024-11-12
dehydroaltenusin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
dehydroaltenusin: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 14824648 |
| MeSH ID | M0251819 |
Synonyms (11)
| Synonym |
|---|
| dehydroaltenusin |
| 6h-dibenzo(b,d)pyran-2,6(4ah)-dione, 3,7-dihydroxy-9-methoxy-4a-methyl-, (4as)- |
| U0VV30G3Y4 , |
| altenusin, dehydro- |
| 3,7-dihydroxy-9-methoxy-4a-methyl-4ah-benzo(c)chromene-2,6-dione |
| unii-u0vv30g3y4 |
| 31186-13-7 |
| (4as)-3,7-dihydroxy-9-methoxy-4a-methylbenzo[c]chromene-2,6-dione |
| HY-100513A |
| CS-0019645 |
| AKOS040741620 |
Research Excerpts
Overview
Dhydroaltenusin is a selective inhibitor of mammalian DNA polymerase alpha (pol alpha) from a fungus (Alternaria tennuis) It was found to be an inhibitor of pol alpha in vitro.
Treatment
| Excerpt | Reference | Relevance |
|---|---|---|
| "Dehydroaltenusin treatment of OK cells engendered fluctuations in the numbers of chromosomes in the OK cells as well as inhibition of cell growth and DNA replication." | ( Growth inhibition and chromosomal instability of cultured marsupial (opossum) cells after treatment with DNA polymerase α inhibitor. Kazama, T; Mizushina, Y; Oshima, T; Sakuma, K; Takemura, M, 2011) | 1.09 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (12)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 8 (66.67) | 29.6817 |
| 2010's | 2 (16.67) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.29
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.29) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (8.33%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (91.67%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||